Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-038651
Filing Date
2020-08-10
Accepted
2020-08-10 08:33:48
Documents
55
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q agle-10q_20200630.htm   iXBRL 10-Q 2568705
2 EX-31.1 agle-ex311_9.htm EX-31.1 16033
3 EX-31.2 agle-ex312_7.htm EX-31.2 15570
4 EX-32.1 agle-ex321_11.htm EX-32.1 7018
5 EX-32.2 agle-ex322_6.htm EX-32.2 6920
  Complete submission text file 0001564590-20-038651.txt   7514366

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA agle-20200630.xsd EX-101.SCH 39749
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE agle-20200630_cal.xml EX-101.CAL 40695
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20200630_def.xml EX-101.DEF 108740
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20200630_lab.xml EX-101.LAB 305047
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20200630_pre.xml EX-101.PRE 222029
11 EXTRACTED XBRL INSTANCE DOCUMENT agle-10q_20200630_htm.xml XML 1451791
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37722 | Film No.: 201087255
SIC: 2834 Pharmaceutical Preparations